Incyte (INCY) said Thursday that Minjuvi, a treatment for relapsed or refractory follicular lymphoma, is being funded in Ontario through the province's Funding Accelerated for Specific Treatments, or FAST program.

The program enables eligible patients to gain access to the treatment sooner while formal reimbursement processes continue, the company said.

Price: 125.89, Change: -0.13, Percent Change: -0.10